Literature DB >> 29540475

Leukocyte integrin Mac-1 (CD11b/CD18, αMβ2, CR3) acts as a functional receptor for platelet factor 4.

Valeryi K Lishko1, Valentin P Yakubenko2, Tatiana P Ugarova1, Nataly P Podolnikova3.   

Abstract

Platelet factor 4 (PF4) is one of the most abundant cationic proteins secreted from α-granules of activated platelets. Based on its structure, PF4 was assigned to the CXC family of chemokines and has been shown to have numerous effects on myeloid leukocytes. However, the receptor for PF4 remains unknown. Here, we demonstrate that PF4 induces leukocyte responses through the integrin Mac-1 (αMβ2, CD11b/CD18). Human neutrophils, monocytes, U937 monocytic and HEK293 cells expressing Mac-1 strongly adhered to immobilized PF4 in a concentration-dependent manner. The cell adhesion was partially blocked by anti-Mac-1 mAb and inhibition was enhanced when anti-Mac-1 antibodies were combined with glycosaminoglycans, suggesting that cell-surface proteoglycans act cooperatively with Mac-1. PF4 also induced Mac-1-dependent migration of human neutrophils and murine WT, but not Mac-1-deficient macrophages. Coating of Escherichia coli bacteria or latex beads with PF4 enhanced their phagocytosis by macrophages by ∼4-fold, and this process was blocked by different Mac-1 antagonists. Furthermore, PF4 potentiated phagocytosis by WT, but not Mac-1-deficient macrophages. As determined by biolayer interferometry, PF4 directly bound the αMI-domain, the major ligand-binding region of Mac-1, and this interaction was governed by a Kd of 1.3 ± 0.2 μm Using the PF4-derived peptide library, synthetic peptides duplicating the αMI-domain recognition sequences and recombinant mutant PF4 fragments, the binding sites for αMI-domain were identified in the PF4 segments Cys12-Ser26 and Ala57-Ser70 These results identify PF4 as a ligand for the integrin Mac-1 and suggest that many immune-modulating effects previously ascribed to PF4 are mediated through its interaction with Mac-1.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Mac-1; PF4; alarmins; chemokine; integrin; macrophage; phagocytosis; platelet

Mesh:

Substances:

Year:  2018        PMID: 29540475      PMCID: PMC5936813          DOI: 10.1074/jbc.RA117.000515

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  Platelets as immune cells: bridging inflammation and cardiovascular disease.

Authors:  Philipp von Hundelshausen; Christian Weber
Journal:  Circ Res       Date:  2007-01-05       Impact factor: 17.367

2.  The carboxyl-terminal tridecapeptide of platelet factor 4 is a potent chemotactic agent for monocytes.

Authors:  D G Osterman; G L Griffin; R M Senior; E T Kaiser; T F Deuel
Journal:  Biochem Biophys Res Commun       Date:  1982-07-16       Impact factor: 3.575

3.  A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation.

Authors:  A Coxon; P Rieu; F J Barkalow; S Askari; A H Sharpe; U H von Andrian; M A Arnaout; T N Mayadas
Journal:  Immunity       Date:  1996-12       Impact factor: 31.745

4.  Platelet Factor 4 Binds to Vascular Proteoglycans and Controls Both Growth Factor Activities and Platelet Activation.

Authors:  Megan S Lord; Bill Cheng; Brooke L Farrugia; Simon McCarthy; John M Whitelock
Journal:  J Biol Chem       Date:  2017-01-23       Impact factor: 5.157

5.  Purification and binding properties of human platelet factor four.

Authors:  R I Handin; H J Cohen
Journal:  J Biol Chem       Date:  1976-07-25       Impact factor: 5.157

6.  Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients.

Authors:  Olga Pervushina; Barbara Scheuerer; Norbert Reiling; Lars Behnke; Jens-M Schröder; Brigitte Kasper; Ernst Brandt; Silvia Bulfone-Paus; Frank Petersen
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

7.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

8.  Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

9.  Atomic description of the immune complex involved in heparin-induced thrombocytopenia.

Authors:  Zheng Cai; Serge V Yarovoi; Zhiqiang Zhu; Lubica Rauova; Vincent Hayes; Tatiana Lebedeva; Qun Liu; Mortimer Poncz; Gowthami Arepally; Douglas B Cines; Mark I Greene
Journal:  Nat Commun       Date:  2015-09-22       Impact factor: 14.919

10.  Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils.

Authors:  A Walz; B Dewald; V von Tscharner; M Baggiolini
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  12 in total

1.  Differential Interaction of Platelet-Derived Extracellular Vesicles With Circulating Immune Cells: Roles of TAM Receptors, CD11b, and Phosphatidylserine.

Authors:  Birgit Fendl; Tanja Eichhorn; René Weiss; Carla Tripisciano; Andreas Spittler; Michael B Fischer; Viktoria Weber
Journal:  Front Immunol       Date:  2018-12-11       Impact factor: 7.561

2.  A Single-Cell Transcriptional Roadmap of the Mouse and Human Lymph Node Lymphatic Vasculature.

Authors:  Menglan Xiang; Rubén Adrián Grosso; Akira Takeda; Junliang Pan; Tove Bekkhus; Kevin Brulois; Denis Dermadi; Sofia Nordling; Michael Vanlandewijck; Sirpa Jalkanen; Maria H Ulvmar; Eugene C Butcher
Journal:  Front Cardiovasc Med       Date:  2020-04-30

Review 3.  Phagocytic Integrins: Activation and Signaling.

Authors:  Alvaro Torres-Gomez; Carlos Cabañas; Esther M Lafuente
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

Review 4.  Cadherins, Selectins, and Integrins in CAM-DR in Leukemia.

Authors:  Hye Na Kim; Yongsheng Ruan; Heather Ogana; Yong-Mi Kim
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

Review 5.  The role of co-infections and secondary infections in patients with COVID-19.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Pneumonia (Nathan)       Date:  2021-04-25

Review 6.  Thy-1 (CD90), Integrins and Syndecan 4 are Key Regulators of Skin Wound Healing.

Authors:  Leonardo A Pérez; Lisette Leyton; Alejandra Valdivia
Journal:  Front Cell Dev Biol       Date:  2022-02-03

7.  Integrin CD11b mediates locus coeruleus noradrenergic neurodegeneration in a mouse Parkinson's disease model.

Authors:  Liyan Hou; Xingyue Qu; Xiaofei Qiu; Ruixue Huang; Xiulan Zhao; Qingshan Wang
Journal:  J Neuroinflammation       Date:  2020-05-06       Impact factor: 8.322

Review 8.  β2 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease.

Authors:  Monika Bednarczyk; Henner Stege; Stephan Grabbe; Matthias Bros
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

Review 9.  Platelets and Their Role in the Pathogenesis of Cardiovascular Events in Patients With Community-Acquired Pneumonia.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

10.  Efferocytosis fuels malignant pleural effusion through TIMP1.

Authors:  Lilan Zhao; Anastasios D Giannou; Yang Xu; Ahmad Mustafa Shiri; Imke Liebold; Babett Steglich; Tanja Bedke; Tao Zhang; Jöran Lücke; Pasquale Scognamiglio; Jan Kempski; Anna Woestemeier; Jing Chen; Theodora Agalioti; Dimitra E Zazara; Diana Lindner; Melanie Janning; Jan K Hennigs; Rajesh M Jagirdar; Ourania S Kotsiou; Sotirios G Zarogiannis; Yasushi Kobayashi; Jacob R Izbicki; Sourav Ghosh; Carla V Rothlin; Lidia Bosurgi; Samuel Huber; Nicola Gagliani
Journal:  Sci Adv       Date:  2021-08-13       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.